Laser Treatment of Benign Pigmented Lesions 

  • Author: Noah S Scheinfeld, MD, JD, FAAD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Aug 1, 2011
 

Overview

Schawlow and Townes were working with microwaves in 1958 when they first proposed a technique for the generation of monochromatic radiation by stimulated emission. They produced monochromatic radiation in the infrared optical region of the electromagnetic spectrum with an alkali vapor used as the active medium. In 1960, Maiman developed stimulated emission of a red-light beam with a wavelength of 694 nm using a ruby crystal. This was the first working laser and is the prototype from which today's lasers are derived.

Since 1960, research and technical advances have adapted lasers to dermatology. In 1963, Goldman first experimented with a normal-mode (500-microsecond pulse duration), 694-nm ruby laser pulse on human skin. The darker the skin color, the more the laser was absorbed. Based on these observations, he speculated that melanin selectively absorbs laser light.

In later studies, Goldman used a Q-switched ruby laser (50-microsecond pulse duration) and found that the damage threshold of pigmented lesions was independent of skin color. This suggested a more selective effect, perhaps at the level of the melanosome. The early work with the ruby laser consisted of ablation techniques. Little bleeding was noted after nonspecific damage to the superficial dermal layers. Small areas of skin could be treated with high-intensity radiation with few complications.

Approximately 20 years later, Polla et al[1] and Dover et al,[2] in separate studies, demonstrated that the Q-switched ruby laser targeted individual melanosomes. Electron microscopic analysis of these thermally damaged targeted melanosomes revealed membrane disruption and disorganization of the internal contents. The destruction of melanosomes is pulse-width-dependent; pulse durations of 40 nanoseconds and 750 nanoseconds both disrupt melanosomes, but longer pulse durations (eg, 400 microseconds) do not damage the melanosomes. This is consistent with the theory of selective photothermolysis, which states that the pulse duration of an emitted laser wavelength must be less than the thermal relaxation time of the targeted object. A typical 1-µm melanosome has a thermal relaxation time of 0.5-1 microseconds.

The cause of melanosomal destruction is unknown. Plasma formation probably does not occur. The peak powers produced with lasers used to interact with melanosomes are quite low for such an occurrence. More likely explanations are shockwave and/or cavitation damage, the photomechanical physical effects produced from thermal expansion, and/or the extreme temperature gradients created within the melanosome. Studies of acoustic waves generated by pulsed irradiation of melanosomes and pigmented cells support this possibility. Melanin absorbs and localizes the high-intensity irradiation from Q-switched lasers, thereby creating a sharp temperature gradient between the melanosome and its surrounding other structures. This gradient leads to thermal expansion and the generation and propagation of acoustic waves, which can mechanically damage the melanosome-laden cells.

Tissue repair following laser-induced melanosomal disruption demonstrates a 2-staged initial transient cutaneous depigmentation followed by subsequent repigmentation weeks later. Black guinea pig skin irradiated with 40-nanosecond Q-switched ruby pulses at a radiant exposure of 0.4 J/cm2 or greater whitens immediately, fades in 20 minutes, depigments 7-10 days later, and then repigments 4-8 weeks after treatment. The repigmented guinea pig skin displays a persistent leukotrichia, which can last up to 4 months after laser irradiation. Guinea pig skin exposed to a radiant exposure of less than that of the threshold exposure (< 0.3 J/cm2) undergoes paradoxical melanogenesis. This may be due to either a sublethal change in the melanosome (interfering with the normal feedback inhibition of melanogenesis) or simply postinflammatory hyperpigmentation. Further studies are required to evaluate the therapeutic implications of this paradoxical reaction.

Laser irradiation leads to histologic melanosomal disruption and vacuolization of pigment-laden cells in the basal layer. Both keratinocytes and melanocytes exhibit pigment and nuclear material condensation at the periphery of laser-irradiated cells. This leads to a characteristic "ring-cell" appearance. Epidermal necrosis and regeneration of a pigmented epidermis follow over the next 7 days.

Observations of the effects on human skin are similar to those of guinea pig skin. The Q-switched ruby laser targets melanosomes. Subsequently, sloughing of the killed pigmented cells occurs. Transient hypopigmentation is followed by gradual repigmentation to the normal constitutive color. Other short-pulsed, high-fluence specific pigmented lesion lasers produce similar clinical and histologic findings in human skin.

Three action-spectrum studies have analyzed the ability of different-wavelength pulsed lasers to disrupt cutaneous pigment. Anderson et al evaluated the effects of a Q-switched Nd:YAG laser with a pulse duration of 10-12 nanoseconds, at 3 distinct wavelengths (355, 532, and 1064 nm), on a guinea pig's skin. The threshold exposure for immediate skin whitening, the sign of laser-induced melanosomal changes, required an energy fluence of 0.11, 0.2, and 1 J/cm2 at 355, 532, and 1064 nm, respectively.

These findings show that the threshold exposure dose is wavelength-dependent. Furthermore, longer wavelengths (which are less well-absorbed by melanin) require a higher energy fluence to induce these changes. At all evaluated wavelengths, electron microscopic examination revealed disrupted melanosomes within keratinocytes and melanocytes. Histologically, irradiated basal cells show a characteristic ring-cell appearance. This appearance is thought to be secondary to vacuolization and peripheral condensation of the cellular pigment. As expected, the transient, immediate whitening of the laser-treated area exhibits delayed epidermal depigmentation followed by repigmentation back to constitutive skin color.

Flashlamp-pulsed tunable lasers with a pulse duration of 750 nanoseconds also demonstrate the relationship between wavelength and whitening threshold. The threshold fluence was found to be 0.44, 0.62, 0.76, and 0.86 J/cm2 at 435, 488, 532, and 560 nm, respectively.

Finally, Sherwood et al performed an action-spectrum study of guinea pig skin using a flashlamp-pulsed tunable laser with a pulse duration of 300 nanoseconds at 5 different wavelengths (504, 590, 720, and 750 nm). They found the 504-nm wavelength produced the most pigment-specific injury because the longer wavelengths caused disruption of the basement membrane with pigmentary incontinence.

In current practice, numerous lasers can specifically target pigmented lesions, including red-light lasers (eg, 694-nm ruby, 755-nm alexandrite), green-light lasers (eg, 510-nm pulsed dye,[3, 4, 5, 6] 532-nm frequency-doubled Nd:YAG), and near-infrared lasers (eg, 1064 nm Nd:YAG). The wide range of lasers that can be used to treat pigment is a result of the broad absorption spectrum of melanin. Even so, other less pigment-specific lasers have been used to treat pigmented lesions, including the argon, krypton, copper, carbon dioxide, and, most recently, Er:YAG lasers.

The carbon dioxide laser exerts its effect on tissue by simple vaporization of water-containing cells. Textural skin changes and scarring may result from this nonselective destruction. A very low-wattage carbon dioxide laser appears to reduce the risk of scarring and has been used effectively to treat superficial epidermal pigmented lesions, such as solar lentigines. The Er:YAG laser also vaporizes water-containing cells and may more precisely ablate superficial layers of skin compared with the carbon dioxide laser. Note that wavelengths not selectively absorbed by melanin indiscriminately destroy pigmented and nonpigmented structures in the skin.

Alternatively, lasers with wavelengths that are both (1) preferentially absorbed by melanin over other cutaneous chromophores (eg, hemoglobin) and (2) penetrate to the depth of the targeted pigment can be used to more selectively target cutaneous pigment. Lasers emitting wavelengths of 630-1100 nm may provide selective melanosome absorption, good skin penetration because of these longer wavelengths, and selection of melanin over hemoglobin.

Pulsed lasers with appropriate wavelengths have a distinct theoretical advantage over continuous-wave devices in the selective destruction of cutaneous pigment. The green and blue light (488 and 514 nm, respectively) of the argon laser is specifically absorbed by melanin. The problem with the system is that it functions as a continuous-wave laser. Thus, although this laser selectively targets the melanin chromophore, the heat produced dissipates from the absorbing melanosomes, causing thermal damage to surrounding tissue with resultant hypopigmentation and potential scarring. Similar findings can ensue after use of the krypton (520-530 nm) and copper (511 nm) lasers.

Pigment-specific lasers can be divided into 3 categories: (1) green, (2) red, and (3) near-infrared. Green-light lasers are further subdivided into both pulsed and nonpulsed systems. Red-light lasers are subdivided into short-pulsed (Q-switched) and long-pulsed (normal-mode) systems. The currently available near-infrared laser is short-pulsed (Q-switched). Green-light lasers do not penetrate as deeply into the skin as the red-light and near-infrared lasers, owing to their shorter wavelengths. Therefore, green-light lasers are effective only in the treatment of epidermal pigmented lesions, as demonstrated in the images below.

Solar lentigo before treatment with a pigmented leSolar lentigo before treatment with a pigmented lesion laser treatment. Clearance of solar lentigo after one laser treatmeClearance of solar lentigo after one laser treatment. Solar lentigines before treatment with a pigmentedSolar lentigines before treatment with a pigmented lesion laser treatment. Clearance of solar lentigines after one laser treaClearance of solar lentigines after one laser treatment.

From 2001-2006, most investigators have studied and reported good effects with Q-switched lasers. Q-switched lasers are considered by some authorities to be the lasers of choice for pigmented melanocytic processes. This has been underlined by reports that Q-switched laser is a treatment of choice for the nevus of Ota.[7] Fraxel laser may be an option for pigmented lesions and pigmenation itself.[8]

Note that laser treatments for congenital melanocytic nevi remain controversial because of the potential to induce malignancy or mask the development of malignancy. This debate is international in scope.[9] All discussions in this regard are speculative and parallel the general poor understanding of the natural history of the development of melanoma.

A randomized clinical pilot reserach study compared the 595- and 607-nm wavelength pulsed dye lasers for the therapy of pigmented lesions and found them equally effective.[10]

Related articles include Laser Revision of Scars; Laser Treatment of Acquired and Congenital Vascular Lesions; Laser Tissue Resurfacing; and Lasers, General Principles and Physics.

Next

Green-Light Pulsed and Green-Light Nonpulsed Lasers

Green-light pulsed lasers

These lasers produce energy with pulses shorter than the thermal relaxation time of melanosomes. Examples of these lasers are the flashlamp-pumped pulsed dye and frequency-doubled Q-switched Nd:YAG lasers. The flashlamp-pumped pulsed dye laser produces a 510-nm wavelength and 300-nanosecond pulse of energy, whereas the frequency-doubled Q-switched Nd:YAG laser produces a 532-nm wavelength and a 5- to 10-nanosecond pulse of energy. Both lasers produce excellent results when used to treat epidermal pigmented lesions such as solar lentigines and ephelides. Because the green wavelength of these lasers is also well absorbed by oxyhemoglobin, purpura formation may occur following laser irradiation. The purpura resolves 1-2 weeks after treatment, with resolution or lightening of the clinical lesion 4-8 weeks after treatment. Purpura occasionally leads to postinflammatory hyperpigmentation.

Flashlamp-pumped pulsed dye laser treatment results in excellent clearing of epidermal pigmented lesions (eg, lentigines, ephelides, seborrheic keratoses, café au lait macules). In a study of 492 benign epidermal pigmented lesions in 65 patients, 50% of the treated lesions cleared completely after one treatment when treated at a fluence of 2-3.5 J/cm2. Another 33% of the treated lesions were lightened considerably. Ninety percent of treated epidermal pigmented lesions can be cleared after 3 treatments.

Treatment results can be affected by anatomic location. Although up to 90% of hand and facial lentigines may be cleared, less favorable results are usually seen following treatment of trunk or leg epidermal pigmented lesions. A typical treatment response includes purpura lasting 5-7 days, followed by subsequent sloughing of the treated lesion at 7-14 days. The underlying new skin is pink for 2-3 days but fades to normal skin color with rare textural changes or scarring.

In another study, 25 patients with solar lentigines showed excellent laser-induced clearing after 1-2 treatments. Fourteen patients with café au lait macules showed complete clearing after 3-6 treatments. Two patients with nevus spilus and 2 patients with Becker nevi showed clearing with up to 6 treatments. As a general rule, this laser produces a variable response in epidermal pigmented lesions such as café au lait macules, Becker nevi, and epidermal melasma.

Epidermal postinflammatory hyperpigmentation also may respond. Dermal pigmented lesions predominantly show little to no response. Because some lesions show a variable clinical response, spot testing the treatment areas of the respective lesion may be prudent prior to engaging in a full treatment. Even when café au lait macules and Becker nevi show resolution after treatment, recurrences have been reported. Lesions may recur because of the impact of these lasers on melanosomes, with little effect on the pigment-producing melanocytes.

Careful sun protection may retard but will not prevent recurrence. Because melasma occurs secondary to a combination of genetic, sun-induced, and hormonal factors, successful laser treatment is the exception rather than the rule with the use of this laser.

The Q-switched Nd:YAG laser is a solid-state, high-fluence, short-pulsed (10-20 nanoseconds) laser that emits at a wavelength of 1064 nm. By placing doubling crystals in the laser beam's path, the wavelength is effectively halved to 532 nm. Epidermal lesions such as lentigines and café au lait macules can be lightened considerably by the frequency-doubled Q-switched Nd:YAG. In one study, 84% of lentigines in 17 patients lightened by at least 50% after several treatments at 2-5 J/cm2. Postoperative purpura developed in all patients, and 25% of treated individuals showed transient hyperpigmentation. The degree of response to the laser at this wavelength is proportional to the amount of pigment chromophore present at the treatment site. When a high fluence is delivered through a small spot size, whitening of the skin is noted. This is then followed by pinpoint bleeding leading to a hemorrhagic crust, which falls off in 7-10 days.

Green-light nonpulsed (quasi-continuous wave) lasers

Nonpulsed, quasi–continuous-wave green-light lasers such as the copper vapor (511 nm), krypton (520-530 nm), and variable pulse with potassium-titanyl-phosphate (KTP) (532 nm) lasers share some characteristics with the aforementioned pulsed lasers. However, because the thermal relaxation time of the melanosome is exceeded using these lasers, they do not produce the same consistent clinical results. Although small epidermal pigmented lesions may be successfully cleared, more treatment sessions are usually necessary to achieve similar results to those seen with pulsed green lasers. Others have tried robotized scanning devices to allow occasional effective treatment of larger lesions such as café au lait macules. These lasers are not useful in the treatment of dermal pigmented lesions such as nevi of Ota.

Note that the epidermal pigmented lesion response following treatment with a noncoherent flashlamp intense pulsed light source is somewhere between that of the pulsed lasers and that of nonpulsed systems.

Previous
Next

Red-Light Pulsed Lasers

The 2 currently available red-light pulsed pigmented lesion lasers are the Q-switched ruby and Q-switched alexandrite lasers. The Q-switched ruby laser emits a 694-nm beam with a 20- to 50-nanosecond pulse duration. The Q-switched alexandrite laser emits a 755-nm wavelength with a pulse duration of 50-100 nanoseconds. The longer wavelengths of these lasers allow deeper penetration into the dermis. Their mechanism of action on melanin-containing melanosomes and melanocytes involves selective photothermolysis, photoacoustical mechanical disruption, and chemical alteration of the target tissue. Photoacoustic mechanical disruption is caused by rapid thermal tissue expansion, creating pressure waves that fragment pigment particles in the dermis. Within the dermis, absorption of the laser energy by melanin-rich stage III and IV melanosomes causes selective pigment destruction.

Previous
Next

Q-Switched Ruby Laser and Q-Switched Alexandrite Laser

Rapidly pulsed Q-switched lasers produce ultrashort energy bursts effective at lightening brown, blue, and black macules. The use of Q-switching laser pulses initially involved the Q-switched ruby laser. Subsequently, the Q-switched Nd:YAG laser (532 nm and 1064 nm) and the Q-switched alexandrite laser (755 nm) were used for similar purposes.[11]

The pulse duration of Q-switched pulses lasts nanoseconds. Their effects might involve photoacoustic causal damage of melanosomes. Melanosomes are 0.7 µm in diameter in types I and II skin and 1 µm or more in diameter in darker skin types. Melanosomes, due to their small size, have very short thermal relaxation times. Q-switched lasers, with pulses in the nanosecond range, provide the most destructive effects on melanosomes with the least damage to surrounding cellular structures.

In 2007, Trafeli et al[12] reported on 18 patients with lentigos. Each received a single, variable pulse-width alexandrite laser treatment. Test sites were performed with a 10-mm spot size and up to 4 pulse widths (3, 20, 40, and 60 milliseconds). In some cases, they did not use epidermal cooling. Three full treatments were performed 3 weeks later using optimum test parameters, and patients were evaluated at 3 and 6 weeks. Patients with darker lentigines had superior lentigo clearance than patients with lighter-colored lentigines. For lentigo clearance, briefer pulse widths and treatment without cryogen cooling both, independently, decreased the fluence threshold.

In 2001, Suh et al[13] reported 71 Korean adult patients with superficial pigmented lesions (lentigines and solar lentigines) who demonstrated a very good response rate to multiple Q-switched Nd:YAG laser treatments.

In 2003, Downs et al[14] noted that the combination of the Q-switched Nd:YAG laser for café au lait spots, Becker nevi, speckled nevi, and congenital melanocytic nevi and the 755-nm long-pulsed alexandrite laser for hair removal effectively treated melanocytic processes in children. Congenital melanocytic nevi responded in 3 treatments; congenital hairy melanocytic nevi were treated an average of 5 times with a 50-60% lightening response in 3 of 5 cases; speckled nevus required an average of 6 treatments. Becker nevi in this study were treated as many as 8 times.

The Q-switched 1064-nm laser seems to facilitate the lowest melanin absorption and the deepest tissue penetration of the Q-switched lasers. The Q-switched Nd:YAG laser is the optimal laser for treating melanocytic processes in skin types III, IV, V, and VI, in particular for dermal processes such as the nevi of Ota or Ito, as shown in the images below. This laser can also be used to treat blue nevi. Treatment is usually performed with a 4- to 8-mm spot size at a fluence of 3-6 J/cm2.

Nevus of Ota before pigmented lesion laser treatmeNevus of Ota before pigmented lesion laser treatment. Nevus of Ota after 3 laser treatments. Nevus of Ota after 3 laser treatments.

Freckles and lentigos improve after treatment with Q-switched lasers. In 2004, Hamilton[15] noted that freckles lighten with the Q-switched, 532-nm laser, usually with one treatment, but recur with solar exposure.

The Q-switched ruby laser is made with a ruby (aluminum oxide) crystal that has been grown in the presence of chromium. This combined crystal is surrounded by a helical flash lamp. The laser, in its natural state, produces a train of nonuniform pulses. In the Q-switched mode, very high peak powers (>1 X 108 W/cm2 per pulse) can be attained with each pulse. Most melanocytic processes are treated at a fluence of 4-6 J/cm2 with the Q-switched ruby laser.

Ruby laser light penetrates approximately 1 mm into the skin, is well absorbed by melanin, and is minimally absorbed by hemoglobin. Thus, this laser can be used for dermal pigmented lesions while avoiding vascular dermal structures. Epidermal pigmented lesions (eg, lentigines, ephelides) usually clear after 1-4 treatments with the Q-switched ruby laser. Taylor et al[16] reported 29 lentigines that totally cleared after only one treatment. Café au lait macules, nevus spilus, and Becker nevi also may respond to treatment with this laser. Ashinoff et al[17] treated 15 café au lait macules and found significant lightening after an average of 6 treatments. Frequent recurrences are the general rule after treatment of café au lait macules, nevus spilus, and Becker nevi.

The Q-switched ruby laser is highly effective in treating dermal pigmented lesions (eg, nevus of Ito and Ota). The long wavelength successfully targets the deep spindle cell–shaped dermal melanocytes. Histologically, they appear to be destroyed. Geronemus[18] treated 15 patients with nevus of Ota up to 7 times with the Q-switched ruby laser. Complete clearing was noted in 4 patients, with significant lightening in the others. Taylor et al[19] treated 9 patients with nevus of Ota and had similar excellent results. In a large Japanese study, more than 100 individuals were treated with the Q-switched ruby laser. In this study, the degree of lightening was related to the number of treatments. Total clearing was seen in all individuals treated at least 4 times.[20]

Lower eyelid hyperpigmentation secondary to dermal pigmentation may respond to treatment with the Q-switched ruby laser. Several treatments are usually required. Mixed epidermal and dermal lesions (eg, postinflammatory hyperpigmentation, melasma) respond better to this laser than the green pulsed lasers; however, the results remain somewhat variable.[21]

Acquired bilateral nevi of Ota–like macules (Hori nevi) manifest as dermal pigmented macules. Hori nevi occur most frequently in middle-aged Asian women. In 2003, Manuskiatti et al[22] reported the efficacy of Q-switched ruby laser for lightening of Hori nevi. They noted the beneficial effects of epidermal ablation using the scanned carbon dioxide laser before the Q-switched ruby laser. Approximately 15% of patients experienced hypopigmentation at 3-month follow-up, but none had hypopigmentation at 16 months.

The Q-switched ruby laser may be used in the treatment of congenital nevi. Although occasional significant clinical lightening may occur, recurrence of pigmentation is the general rule. Histologically, residual nevomelanocytes were seen in the deeper dermis. Note that some controversy remains about the long-term effect of laser treatment on the melanocytes contained within a congenital nevus. Despite this controversy, a case of Q-switched ruby laser–induced melanoma in a previously laser-treated congenital nevus has never been documented.

In 2003, Westerhof and Gamei[23] reported that the Q-switched ruby laser demonstrated excellent effects at completely removing flat (nonpalpable) acquired junctional melanocytic nevi, but not compound nevi. Westerhof and Gamei[23] noted that 1-3 treatments yielded good effects and did not result in scarring or adverse pigmentary alterations.

The Q-switched alexandrite laser is a solid-state laser, which emits light at 755 nm with a pulse duration of 50-100 nanoseconds. Fewer data have been published about this laser compared with the Q-switched ruby laser. However, because the wavelength and pulse duration are similar to those of the Q-switched ruby laser, results should be somewhat similar. A good response has been seen in the treatment of lentigines and café au lait macules. Dermal pigmented lesions (eg, nevi of Ota) also respond.[24]

In one study by Rosenbach et al,[25] the Q-switched alexandrite laser was compared with the Q-switched Nd:YAG laser (1064 nm) for the treatment of benign melanocytic nevi in 18 patients. Both lasers produced significant improvement after 3 treatments, although the Q-switched alexandrite laser was slightly more effective. Twelve-month follow-up of 12 of the treated patients showed no evidence of recurrence or pigment darkening.

Because of its high melanin absorption, permanent hypopigmentation more commonly manifests with the Q-switched alexandrite laser than with other Q-switched lasers operating at different wavelengths.

In 2005, Kim and Kang[26] reported on the treatment of congenital nevi with the Q-switched alexandrite laser in a Korean population with and without intermittent use of a carbon dioxide laser. They concluded that the Q-switched alexandrite laser worked similarly to other Q-switch mode lasers to lighten congenital melanocytic nevi but that repigmentation commonly recurred months after treatment Kim and Kang treated 37 patients with the Q-switched alexandrite laser alone and 16 patients also with carbon dioxide laser treatment between Q-switched alexandrite laser treatments. Treatment using the Q-switched alexandrite laser and carbon dioxide laser resulted in a substantially enhanced improvement score (3.06 +/- 1.18) as contrasted to persons exposed to the Q-switched alexandrite laser alone (2.43 +/- 1.07; P = .0393).

Kim and Kang[26] noted adverse effects with treatment. Thirty-five nevi (67.3%) had textural changes to the skin, 2 nevi (3.8%) had depressed scar formation, 4 nevi had (7.5%) hypertrophic changes, and 12 nevi (23%) showed no changes. Forty-eight weeks after the final Q-switched alexandrite laser treatment, hypopigmentation was noted in 16 patients (30%) and hyperpigmentation was seen in 15 patients (28%). Repigmentation to a brown-to-black macule occurred in 44 (83%) of 53 patients. The mean period for this to occur was 5.45 +/- 3.93 months.

Previous
Next

Normal-Mode Alexandrite and Ruby Lasers

Long-pulsed ruby (300- to 3000-microsecond pulses) and alexandrite (2- to 20-microsecond pulses) lasers have been shown to be effective in the treatment of Q-switched ruby laser–resistant congenital nevi and other pigmented lesions. These lasers also may be of use in laser-assisted hair removal.

The normal-mode alexandrite laser emits light at a wavelength of 755 nm with 2- to 20-microsecond pulse durations. This laser is effective in removing pigmented hair. No data have been published on its use in pigmented lesions.

The normal-mode ruby laser is also highly effective for removing pigmented hair. The Japanese have the only published experience with the use of long-pulsed lasers for pigmented lesions. Congenital nevi treated 4 times showed significant clearing of pigmentation. Treated skin was almost indistinguishable from the normal surrounding skin.

Wang et al[27] compared the Q-switched alexandrite laser to intense pulsed light in the treatment of freckles and lentigines. They found that the Q-switched alexandrite laser was superior to intense pulsed light for freckle treatment but that the intense pulsed light was preferred for lentigines in Asian persons.

Kagami et al[28] found the Q-switched alexandrite laser was not a useful treatment for nevus spilus or café au lait spots

Geist and Phillips[29] noted the development of chrysiasis after Q-switched ruby laser treatment of solar lentigines.

Previous
Next

Near-Infrared Pulsed Lasers

The Q-switched Nd:YAG laser produces a 1064-nm wavelength beam with a pulse duration of 10 nanoseconds. Melanin does not absorb the 1064-nm wavelength well. Thus, the 1064-nm wavelength is not ideal for the treatment of benign pigmented lesions. Despite less absorption of this wavelength by melanin compared with the green- and red-light lasers, its advantage lies in its ability to penetrate more deeply into the skin (up to 4-6 mm). This laser may be more useful in the treatment of lesions in individuals with darker skin tones. Similar to the Q-switched ruby and alexandrite lasers, the Q-switched Nd:YAG laser is highly effective for clearing nevi of Ota. Histologically, the findings at 1064 nm are identical to those of the Q-switched ruby laser. Ring cells representing vacuolated pigmented cells with peripheral condensation of pigment are detected in the epidermal basal cell layer.

Previous
Next

Nonselective Laser Techniques: Carbon Dioxide and Er:YAG Lasers

The carbon dioxide laser (10,600 nm) and the Er:YAG laser (2940 nm) emit infrared laser energy. The Er:YAG laser produces much less thermal damage than is seen with the carbon dioxide laser. Nevertheless, even the carbon dioxide laser, when used with a low fluence, produces only limited thermal necrosis.

In a study evaluating carbon dioxide laser treatment of 146 solar lentigines, 10% cleared completely and two thirds lightened considerably. Thermal damage occurred in the basal cell layer (vacuolization and spindling of the melanocytes and keratinocytes). This damage led to epidermal necrosis 24 hours later with subsequent dermal-epidermal separation. Minimal dermal thermal damage occurred. Sloughing of the damaged epidermis was followed by subsequent reepithelialization.

Previous
Next

Fractional Photothermolysis

In 2007, Naito[30] reported on laser treatment of 6 women with Fitzpatrick skin types III-IV using fractional photothermolysis. Treatments were performed at 4-week intervals, and each woman was treated 3-4 times. Imaging studies were performed, and Naito found that all patients who participated in the study experienced at least 20% reduction in their melasma. Three obtained 50% improvement, 2 obtained 30% improvement, and 1 obtained 20% improvement.

Fraxel laser has continued to show a good safety profile. Grader et al studied 961 patients with successive 1550-nm erbium-doped fraxel laser treatments. The incidence of adverse effects was low (< 2%), with acneiform eruption and herpes simplex virus infection remaining among the most significant.

In 2008, Kouba et al reported the successful treatment of the nevus of Ota with fractional photothermolysis using a fractionated 1440-nm Nd:YAG laser.

Previous
Next

Conclusion

Several pigment-specific lasers can effectively treat epidermal and dermal pigmented lesions. Lasers are most effective in treating epidermal pigmented lesions (eg, lentigines, ephelides). Variable responses can be expected in café au lait macules, Becker nevi, nevus spilus, and melasma. Nevus of Ota is unique in that near-total clearance is often seen after laser treatment. New, long-pulsed, pigment-specific lasers may further enhance the clinical results obtained in resistant pigmented lesions and other conditions. Future lasers for pigmented lesion treatment may selectively target melanocytes rather than melanosomes. The controversy over laser treatment of congenital nevi will be resolved once thousands of treated lesions are monitored for several decades.

Table. Summary of Lasers and Their Efficacy (Open Table in a new window)

Benign Nonnevocellular Epidermal Pigmented Lesions Dermal Mixed
Q-switched



ruby laser (694 nm)



ExcellentExcellentPoor
Q-switched



Nd:YAG (1064 nm)



FairExcellentPoor
Q-switched



Nd:YAG (532 nm)



ExcellentPoor to fairPoor
Pigmented



Dye (510 nm)



ExcellentFairPoor
Alexandrite



755 nm



GoodGoodPoor
Previous
 
Contributor Information and Disclosures
Author

Noah S Scheinfeld, MD, JD, FAAD  Assistant Clinical Professor, Department of Dermatology, Columbia University College of Physicians and Surgeons; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, and New York Eye and Ear Infirmary; Private Practice

Noah S Scheinfeld, MD, JD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Optigenex Consulting fee Independent contractor

Coauthor(s)

David J Goldberg, MD, JD  Clinical Professor of Dermatology, Director of Laser Research, Mount Sinai School of Medicine of New York University; Chief of Dermatologic Surgery, Chief of MOHS Surgery, Clinical Associate Professor of Dermatology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School; Attending Physician, Department of Dermatology, Hackensack University Medical Center; Adjunct Professor of Law, Fordham University School of Law; Chief of Dermatologic Surgery, Department of Dermatology, Veterans Affairs Medical Center of East Orange, NJ

David J Goldberg, MD, JD is a member of the following medical societies: American Academy of Dermatology, American College of Legal Medicine, American College of Mohs Surgery, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, European Academy of Dermatology and Venereology, International Society for Dermatologic Surgery, and Skin Cancer Foundation

Disclosure: Nothing to disclose.

Specialty Editor Board

Tina S Alster, MD  Clinical Professor, Department of Dermatology, Georgetown University School of Medicine; Director, Washington Institute of Dermatologic Laser Surgery

Tina S Alster, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, and Medical Society of the District of Columbia

Disclosure: Home Skinovations Ownership interest Other

Michael J Wells, MD  Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Mary Farley, MD  Dermatologic Surgeon/Mohs Surgeon, Anne Arundel Surgery Center

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References
  1. Polla LL, Margolis RJ, Dover JS, et al. Melanosomes are a primary target of Q-switched ruby laser irradiation in guinea pig skin. J Invest Dermatol. Sep 1987;89(3):281-6. [Medline].

  2. Dover JS, Margolis RJ, Polla LL, et al. Pigmented guinea pig skin irradiated with Q-switched ruby laser pulses. Morphologic and histologic findings. Arch Dermatol. Jan 1989;125(1):43-9. [Medline].

  3. Alster TS. Complete elimination of large cafe-au-lait birthmarks by the 510-nm pulsed dye laser. Plast Reconstr Surg. Dec 1995;96(7):1660-4. [Medline].

  4. Alster TS, Williams CM. Café-au-lait macule in type V skin: successful treatment with a 510 nm pulsed dye laser. J Am Acad Dermatol. Dec 1995;33(6):1042-3. [Medline].

  5. Fitzpatrick RE, Goldman MP, Ruiz-Esparza J. Laser treatment of benign pigmented epidermal lesions using a 300 nsecond pulse and 510 nm wavelength. J Dermatol Surg Oncol. Apr 1993;19(4):341-7. [Medline].

  6. Grekin RC, Shelton RM, Geisse JK, Frieden I. 510-nm pigmented lesion dye laser. Its characteristics and clinical uses. J Dermatol Surg Oncol. Apr 1993;19(4):380-7. [Medline].

  7. Lee WJ, Han SS, Chang SE, et al. Q-Switched Nd:YAG Laser Therapy of Acquired Bilateral Nevus of Ota-like Macules. Ann Dermatol. Aug 2009;21(3):255-60. [Medline]. [Full Text].

  8. Jadotte YT, Schwartz RA. Melasma: insights and perspectives. Acta Dermatovenerol Croat. Jul 2010;18(2):124-9. [Medline].

  9. Bukvic; Mokos Z, Lipozencic J, Ceovic R, Stulhofer Buzina D, Kostovic K. Laser therapy of pigmented lesions: pro and contra. Acta Dermatovenerol Croat. Sep 2010;3:185-9. [Medline].

  10. Chern PL, Domankevitz Y, Ross EV. Pulsed dye laser treatment of pigmented lesions: a randomized clinical pilot study comparison of 607- and 595-nm wavelength lasers. Lasers Surg Med. Dec 2010;10:705-9. [Medline].

  11. Kilmer SL. Laser eradication of pigmented lesions and tattoos. Dermatol Clin. Jan 2002;20(1):37-53. [Medline].

  12. Trafeli JP, Kwan JM, Meehan KJ, et al. Use of a long-pulse alexandrite laser in the treatment of superficial pigmented lesions. Dermatol Surg. Dec 2007;33(12):1477-82. [Medline].

  13. Suh DH, Han KH, Chung JH. The use of Q-switched Nd:YAG laser in the treatment of superficial pigmented lesions in Koreans. J Dermatolog Treat. Jun 2001;12(2):91-6. [Medline].

  14. Downs AM, Rickard A, Palmer J. Laser treatment of benign pigmented lesions in children: effective long-term benefits of the Q-switched frequency-doubled Nd:YAG and long-pulsed alexandrite lasers. Pediatr Dermatol. Jan-Feb 2004;21(1):88-90. [Medline].

  15. Hamilton MM. Laser treatment of pigmented and vascular lesions in the office. Facial Plast Surg. Feb 2004;20(1):63-9. [Medline].

  16. Taylor CR, Anderson RR. Treatment of benign pigmented epidermal lesions by Q-switched ruby laser. Int J Dermatol. Dec 1993;32(12):908-12. [Medline].

  17. Ashinoff R, Geronemus RG. Q-switched ruby laser treatment of labial lentigos. J Am Acad Dermatol. Nov 1992;27(5 Pt 2):809-11. [Medline].

  18. Geronemus RG. Q-switched ruby laser therapy of nevus of Ota. Arch Dermatol. Dec 1992;128(12):1618-22. [Medline].

  19. Taylor CR, Flotte TJ, Gange RW, Anderson RR. Treatment of nevus of Ota by Q-switched ruby laser. J Am Acad Dermatol. May 1994;30(5 Pt 1):743-51. [Medline].

  20. Watanabe S, Takahashi H. Treatment of nevus of Ota with the Q-switched ruby laser. N Engl J Med. Dec 29 1994;331(26):1745-50. [Medline].

  21. Alster TS, Kovak S, Rosenbach A. Comparison of the Q-switched alexandrite (755 nm) and Q-switched Nd: YAG (1064 nm) lasers in the treatment of infraorbital dark circles. Dermatol Surg. 2001.

  22. Manuskiatti W, Sivayathorn A, Leelaudomlipi P, Fitzpatrick RE. Treatment of acquired bilateral nevus of Ota-like macules (Hori's nevus) using a combination of scanned carbon dioxide laser followed by Q-switched ruby laser. J Am Acad Dermatol. Apr 2003;48(4):584-91. [Medline].

  23. Westerhof W, Gamei M. Treatment of acquired junctional melanocytic naevi by Q-switched and normal mode ruby laser. Br J Dermatol. Jan 2003;148(1):80-5. [Medline].

  24. Alster TS, Williams CM. Treatment of nevus of Ota by the Q-switched alexandrite laser. Dermatol Surg. Jul 1995;21(7):592-6. [Medline].

  25. Rosenbach A, Williams CM, Alster TS. Comparison of the Q-switched alexandrite (755 nm) and Q-switched Nd:YAG (1064 nm) lasers in the treatment of benign melanocytic nevi. Dermatol Surg. Apr 1997;23(4):239-44; discussion 244-5. [Medline].

  26. Kim S, Kang WH. Treatment of congenital nevi with the Q-switched Alexandrite laser. Eur J Dermatol. Mar-Apr 2005;15(2):92-6. [Medline].

  27. Wang CC, Sue YM, Yang CH, Chen CK. A comparison of Q-switched alexandrite laser and intense pulsed light for the treatment of freckles and lentigines in Asian persons: a randomized, physician-blinded, split-face comparative trial. J Am Acad Dermatol. May 2006;54(5):804-10. [Medline].

  28. Kagami S, Asahina A, Watanabe R, et al. Treatment of 153 Japanese patients with Q-switched alexandrite laser. Lasers Med Sci. Sep 2007;22(3):159-63. [Medline].

  29. Geist DE, Phillips TJ. Development of chrysiasis after Q-switched ruby laser treatment of solar lentigines. J Am Acad Dermatol. Aug 2006;55(2 Suppl):S59-60. [Medline].

  30. Naito SK. Fractional photothermolysis treatment for resistant melasma in Chinese females. J Cosmet Laser Ther. Sep 2007;9(3):161-3. [Medline].

  31. Alster TS, ed. Manual of Cutaneous Laser Techniques. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000.

  32. Alster TS, Lupton JR. Lasers in dermatology. An overview of types and indications. Am J Clin Dermatol. 2001;2(5):291-303. [Medline].

  33. Anderson RR, Margolis RJ, Watenabe S, Flotte T, Hruza GJ, Dover JS. Selective photothermolysis of cutaneous pigmentation by Q-switched Nd: YAG laser pulses at 1064, 532, and 355 nm. J Invest Dermatol. Jul 1989;93(1):28-32. [Medline].

  34. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science. Apr 29 1983;220(4596):524-7. [Medline].

  35. Apfelberg DB, Maser MR, Lash H, Rivers J. The argon laser for cutaneous lesions. JAMA. May 22-29 1981;245(20):2073-5. [Medline].

  36. Ara G, Anderson RR, Mandel KG, Ottesen M, Oseroff AR. Irradiation of pigmented melanoma cells with high intensity pulsed radiation generates acoustic waves and kills cells. Lasers Surg Med. 1990;10(1):52-9. [Medline].

  37. DePadova-Elder SM, Milgraum SS. Q-switched ruby laser treatment of labial lentigines in Peutz-Jeghers syndrome. J Dermatol Surg Oncol. Dec 1994;20(12):830-2. [Medline].

  38. Ferguson RE Jr, Vasconez HC. Laser treatment of congenital nevi. J Craniofac Surg. Sep 2005;16(5):908-14. [Medline].

  39. Goldberg DJ. Benign pigmented lesions of the skin. Treatment with the Q-switched ruby laser. J Dermatol Surg Oncol. Apr 1993;19(4):376-9. [Medline].

  40. Goldberg DJ. Q-switched ruby laser treatment of benign pigmented lesions: The New Jersey experience (abstract). Lasers Surg Med. 1991;II (suppl 3):65.

  41. Goldberg DJ. Treatment of pigmented and vascular lesions of the skin with the Q-switched Nd: YAG laser (abstract). Lasers Surg Med. 1993;13(suppl 5):55.

  42. Goldberg DJ, Nychay SG. Q-switched ruby laser treatment of nevus of Ota. J Dermatol Surg Oncol. Sep 1992;18(9):817-21. [Medline].

  43. Goldberg DJ, Stampien T. Q-switched ruby laser treatment of congenital nevi. Arch Dermatol. May 1995;131(5):621-3. [Medline].

  44. Graber EM, Tanzi EL, Alster TS. Side effects and complications of fractional laser photothermolysis: experience with 961 treatments. Dermatol Surg. Mar 2008;34(3):301-5; discussion 305-7. [Medline].

  45. Grevelink JM, Lui H, Taylor CR, et al. Update on the treatment of benign pigmented lesions with the Q-switched ruby laser (abstract). Lasers Surg Med. 1992;12(suppl 4):73.

  46. Kilmer SL, Alster TS. Laser treatment of tattoos and pigmented lesions. In: Alster TS, Apfelberg DB, eds. Cosmetic Laser Surgery. New York, NY: Wiley; 1996:111-28.

  47. Kilmer SL, Garden JM. Laser treatment of pigmented lesions and tattoos. Semin Cutan Med Surg. Dec 2000;19(4):232-44. [Medline].

  48. Kilmer SL, Wheeland RG, Goldberg DJ, Anderson RR. Treatment of epidermal pigmented lesions with the frequency-doubled Q-switched Nd:YAG laser. A controlled, single-impact, dose-response, multicenter trial. Arch Dermatol. Dec 1994;130(12):1515-9. [Medline].

  49. Kouba DJ, Fincher EF, Moy RL. Nevus of Ota successfully treated by fractional photothermolysis using a fractionated 1440-nm Nd:YAG laser. Arch Dermatol. Feb 2008;144(2):156-8. [Medline].

  50. Kurban AK, Morrison PR, Trainor SW, Tan OT. Pulse duration effects on cutaneous pigment. Lasers Surg Med. 1992;12(3):282-7. [Medline].

  51. Kwon JW, Jeoung JW, Kim TI, Lee JH, Wee WR. Argon laser photoablation of conjunctival pigmented nevus. Am J Ophthalmol. Feb 2006;141(2):383-6. [Medline].

  52. Langley RG, Burton E, Walsh N, Propperova I, Murray SJ. In vivo confocal scanning laser microscopy of benign lentigines: comparison to conventional histology and in vivo characteristics of lentigo maligna. J Am Acad Dermatol. Jul 2006;55(1):88-97. [Medline].

  53. Lowe NJ, Wieder JM, Sawcer D, Burrows P, Chalet M. Nevus of Ota: treatment with high energy fluences of the Q-switched ruby laser. J Am Acad Dermatol. Dec 1993;29(6):997-1001. [Medline].

  54. Lowe NJ, Wieder JM, Shorr N, Boxrud C, Saucer D, Chalet M. Infraorbital pigmented skin. Preliminary observations of laser therapy. Dermatol Surg. Sep 1995;21(9):767-70. [Medline].

  55. Lu Z, Chen JP, Wang XS. Alexandrite laser irradiation on epidermal melanocytes in treatment of nevus of Ota. Chin Med J. 2003;116:597-601.

  56. Marangoni O, Melato M, Longo L. 808-nm laser with exogenous chromophores for the treatment of benign oral lesions. Photomed Laser Surg. Jun 2005;23(3):324-7. [Medline].

  57. Margolis RJ, Dover JS, Polla LL, et al. Visible action spectrum for melanin-specific selective photothermolysis. Lasers Surg Med. 1989;9(4):389-97. [Medline].

  58. Murphy GF, Shepard RS, Paul BS, Menkes A, Anderson RR, Parrish JA. Organelle-specific injury to melanin-containing cells in human skin by pulsed laser irradiation. Lab Invest. Dec 1983;49(6):680-5. [Medline].

  59. Nanni CA, Alster TS. Treatment of a Becker's nevus using a 694-nm long-pulsed ruby laser. Dermatol Surg. Sep 1998;24(9):1032-4. [Medline].

  60. Nelson JS, Applebaum J. Treatment of superficial cutaneous pigmented lesions by melanin-specific selective photothermolysis using the Q-switched ruby laser. Ann Plast Surg. Sep 1992;29(3):231-7. [Medline].

  61. Ohshiro T, Maruyama Y. The ruby and argon lasers in the treatment of naevi. Ann Acad Med Singapore. Apr 1983;12(2 Suppl):388-95. [Medline].

  62. Ono I, Gunji H, Sato M, et al. Treatment of pigmented seborrheic keratosis by ruby laser irradiation. Eur J Dermatol. 1992;3:206-11.

  63. Redbord KP, Hanke CW. Case reports: clearance of lentigines in Japanese men with the long-pulsed alexandrite laser. J Drugs Dermatol. Jun 2007;6(6):653-6. [Medline].

  64. Scheepers JH, Quaba AA. Clinical experience with the PLDL-1 (Pigmented Lesion Dye Laser) in the treatment of pigmented birthmarks: a preliminary report. Br J Plast Surg. Apr 1993;46(3):247-51. [Medline].

  65. Sherwood KA, Murray S, Kurban AK, Tan OT. Effect of wavelength on cutaneous pigment using pulsed irradiation. J Invest Dermatol. May 1989;92(5):717-20. [Medline].

  66. Tan OT, Morelli JG, Kurban AK. Pulsed dye laser treatment of benign cutaneous pigmented lesions. Lasers Surg Med. 1992;12(5):538-42. [Medline].

  67. Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg Oncol. Sep 1994;20(9):592-7. [Medline].

  68. Teikemeier G, Goldberg DJ. Skin resurfacing with the erbium:YAG laser. Dermatol Surg. Aug 1997;23(8):685-7. [Medline].

  69. Veda S, Imayama S. Normal-mode ruby dates for treating congenital nevi. Arch Dermatol. 1992;133:355.

  70. Waldorf HA, Kauvar AN, Geronemus RG. Treatment of small and medium congenital nevi with the Q-switched ruby laser. Arch Dermatol. Mar 1996;132(3):301-4. [Medline].

  71. Waner M. Recent developments in lasers and the treatment of birthmarks. Arch Dis Child. May 2003;88(5):372-4. [Medline].

  72. Wang HW, Wang JB, Liu YH, Fang K, Jiang GT, Zuo YG. [Analysis of 602 cases of nevus of Ota and study of ultrastructures on the melanocytes]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Oct 2003;25(5):590-3. [Medline].

  73. Watanabe S, Anderson RR, Brorson S, Dalickas G, Fujimoto JG, Flotte TJ. Comparative studies of femtosecond to microsecond laser pulses on selective pigmented cell injury in skin. Photochem Photobiol. Jun 1991;53(6):757-62. [Medline].

  74. Yamashita T, Negishi K, Hariya T, et al. Intense pulsed light therapy for superficial pigmented lesions evaluated by reflectance-mode confocal microscopy and optical coherence tomography. J Invest Dermatol. Oct 2006;126(10):2281-6. [Medline].

  75. Yasuda Y, Tan OT, Kurban AK, Tsukada S. Electron microscopic study on black pig skin irradiated with pulsed dye laser (504 nm). In: Tan O, White RA, White JV, eds. Lasers in Dermatology and Tissue Welding. Los Angeles, Calif: Presented at: International Society for Optical Engineering; January 25, 1991:Paper 1422-07.

  76. Yu SS, Pai S, Neuhaus IM, Grekin RC. Diagnosis and treatment of pigmentary disorders in Asian skin. Facial Plast Surg Clin North Am. Aug 2007;15(3):367-80, vii. [Medline].

Previous
Next
 
Solar lentigo before treatment with a pigmented lesion laser treatment.
Clearance of solar lentigo after one laser treatment.
Solar lentigines before treatment with a pigmented lesion laser treatment.
Clearance of solar lentigines after one laser treatment.
Nevus of Ota before pigmented lesion laser treatment.
Nevus of Ota after 3 laser treatments.
Table. Summary of Lasers and Their Efficacy
Benign Nonnevocellular Epidermal Pigmented Lesions Dermal Mixed
Q-switched



ruby laser (694 nm)



ExcellentExcellentPoor
Q-switched



Nd:YAG (1064 nm)



FairExcellentPoor
Q-switched



Nd:YAG (532 nm)



ExcellentPoor to fairPoor
Pigmented



Dye (510 nm)



ExcellentFairPoor
Alexandrite



755 nm



GoodGoodPoor
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.